Kayne Anderson Rudnick Investment Management
EWTX icon

Kayne Anderson Rudnick Investment Management’s Edgewise Therapeutics EWTX Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-622
Closed -$10.1K – 1028
2025
Q3 		$10.1K Buy
+622
New +$8.82K ﹤0.01% 714

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's EWTX Position: Q4 2025 in Review

Kayne Anderson Rudnick Investment Management sold out of Edgewise Therapeutics (EWTX) in Q4 2025, closing a stake of 622 shares — an estimated $10.1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in EWTX in Q3 2025 and held it in 1 quarter. The position peaked at $10.1K in Q3 2025. 199 funds tracked by Wall St. Rank hold EWTX as of Q4 2025.

  • Kayne Anderson Rudnick Investment Management reported no remaining Edgewise Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 622 Edgewise Therapeutics shares in Q4 2025, an estimated $10.1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Edgewise Therapeutics in Q3 2025 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Edgewise Therapeutics position peaked at $10.1K in Q3 2025.
  • 199 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q4 2025.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.